SCHEMBL19230478

SCHEMBL19230478

Cc1cc([N+](=O)[O-])c(N)c(C)c1C

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.60
ALDH1A1 P00352 6/20 0.50
TSHR P16473 5/20 0.50
CYP3A4 P08684 5/20 0.50
RECQL P46063 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.44
TDP1 Q9NUW8 3/20 0.43
MAPT P10636 2/20 0.42
PKM P14618 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
G6PD P11413 1/20 0.42
MAPK1 P28482 1/20 0.42
KMT2A Q03164 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
APOBEC3G Q9HC16 1/20 0.42
HSD17B10 Q99714 1/20 0.42
GPR35 Q9HC97 1/20 0.41
CTSB P07858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2100657 0.85 TSHR (0.55) CYP1A2ALDH1A1TSHRCYP3A4RECQL
SCHEMBL5203798 0.84 CYP1A2 (0.56) CYP1A2ALDH1A1TSHRCYP3A4RECQL
SCHEMBL6671674 0.84 CYP1A2 (0.52) CYP1A2ALDH1A1TSHRCYP3A4RECQL
SCHEMBL19776318 0.84 CYP1A2 (0.72) CYP1A2ALDH1A1TSHRCYP3A4RECQL
SCHEMBL9107921 0.83 TSHR (0.50) CYP1A2ALDH1A1TSHRCYP3A4RECQL
SCHEMBL30834516 0.82 CYP1A2 (0.55) CYP1A2ALDH1A1TSHRCYP3A4RECQL
SCHEMBL7823140 0.82 CYP1A2 (0.55) CYP1A2ALDH1A1TSHRCYP3A4RECQL
SCHEMBL11133854 0.80 CYP1A2 (0.67) CYP1A2ALDH1A1TSHRCYP3A4RECQL
SCHEMBL31217268 0.79 CYP1A2 (0.70) CYP1A2ALDH1A1TSHRCYP3A4RECQL
SCHEMBL19501351 0.78 TSHR (0.48) CYP1A2ALDH1A1TSHRCYP3A4RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020035031-A1 FUSED RING COMPOUNDS GENENTECH, INC. (US) 2020-02-20 WO disclosed
US-20170233375-A1 CANCER THERAPEUTICS UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2017-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170233375-A1 CANCER THERAPEUTICS RUNX1, CBFB, MCL1 CYP1A2 2612/4885ALDH1A1 1660/4885TSHR 546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.